^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KFA115
i
Other names: NVPKFA115, KFA115, NVP-KFA115, KFA 115, NVP KFA115, KFA-115
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Novartis
Drug class:
Immunomodulator
Related drugs:
9ms
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
P1, N=180, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2026 --> Sep 2027 | Trial primary completion date: Feb 2026 --> Sep 2027
Trial completion date • Trial primary completion date
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • KFA115
over2years
A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
P1, N=220, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2025 --> Feb 2026 | Trial primary completion date: Sep 2025 --> Feb 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tevimbra (tislelizumab-jsgr) • KFA115
3years
A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
P1, N=220, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tevimbra (tislelizumab-jsgr) • KFA115
3years
A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
P1, N=220, Not yet recruiting, Novartis Pharmaceuticals
New P1 trial • Combination therapy
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tevimbra (tislelizumab-jsgr) • KFA115
Share via
